Eli Lilly & Co.’s Mounjaro helped kids as young as 10 control their blood sugar and lose weight in a study that may give ...

PEDS, Mounjaro met the primary and all key secondary endpoints at 30 weeks and showed sustained improvement in glycemic control and continued BMI reduction ...

The U.S. Food and Drug Administration (FDA) has determined that a promotional video featuring Zepbound and Mounjaro ...

Over 2,000 Ozempic and Zepbound lawsuits allege life-threatening side effects as FDA updates warnings and courts weigh ...

Eli Lilly and Company’s LLY stock moved past the 50-day Simple Moving Average (SMA) last week after trading below the same ...

Lots of research suggests such medications must be used indefinitely to maintain weight loss and related health benefits. But ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat ...

GLP-1 medications like Ozempic show promise for multiple health conditions, as experts explore microdosing benefits for blood ...

Demand for Eli Lilly’s LLY blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — remains strong. Despite being on the market for less than three years, both drugs ...

In a revealing preclinical study, the weight-loss drug tirzepatide—already known for fighting obesity and diabetes—unexpectedly slowed the growth of breast cancer tumors in obese mice. Researchers ...

Women's telehealth provider Wisp said on Wednesday it has expanded its weight-care offerings to include sale and doorstep delivery of Novo Nordisk's and Eli Lilly's wildly popular drugs without the ...